Clinical trial
A Phase Ib/II Study of PDR001 Plus Imatinib for Metastatic or Unresectable GIST With Prior Failure of Imatinib, Sunitinib and Regorafenib
NCT03609424 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib/II Study of PDR001 Plus Imatinib for Metastatic or Unresectable GIST With Prior Failure of Imatinib, Sunitinib and Regorafenib
- Lead sponsor
- Asan Medical Center
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 14, 2019
- Completion date
- November 11, 2021
- Enrollment
- 39 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.